RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury

Cell Death and Differentiation

Volumn 23, Issue 9, 2016, Pages 1565-1576

  Newton, K ^a   Dugger, D L ^a   Maltzman, A ^a   Greve, J M ^a   Hedehus, M ^a   Martin Mcnulty, B ^a   Carano, R A D ^a   Cao, T C ^a   Van Bruggen, N ^a   Bernstein, L ^a   Lee, W P ^a   Wu, X ^a   Devoss, J ^a   Zhang, J ^a   Jeet, S ^a   Peng, I ^a   McKenzie, B S ^a   Roose Girma, M ^a   Caplazi, P ^a   Diehl, L ^a   Webster, J D ^a   Vucic, D ^a   more..

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CERULETIDE; CYTOKINE; DEXTRAN SULFATE; LIPOPOLYSACCHARIDE; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE LIKE; PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 1; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; MLKL PROTEIN, MOUSE; PROTEIN KINASE; RIPK1 PROTEIN, MOUSE; RIPK3 PROTEIN, MOUSE; TNFAIP3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BRAIN EDEMA; CATALYSIS; CONTROLLED STUDY; CYTOKINE STORM; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; ENZYME DEFICIENCY; ENZYME INACTIVATION; EXON; EXPERIMENTAL BRAIN INJURY; EXPERIMENTAL INFLAMMATION; EXPERIMENTAL INJURY; EXPERIMENTAL PANCREATITIS; FEMALE; GENE DELETION; GENE DOSAGE; HEART INFARCTION; HYPOTHERMIA; INTESTINE EPITHELIUM CELL; KIDNEY ISCHEMIA; LIPOPOLYSACCHARIDE-INDUCED SEPSIS; MALE; MORBIDITY; MOUSE; MOUSE MODEL; NECROPTOSIS; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PSORIASIS; REPERFUSION INJURY; TISSUE INJURY; TRANSGENE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MORTALITY; PANCREATITIS; PATHOLOGY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; APOPTOSIS; CERULETIDE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PANCREATITIS; PROTEIN KINASES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; REPERFUSION INJURY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3;

EID: 84968538437     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.46     Document Type: Article

References (60)

1. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
2. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
3. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
4. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
5. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-453.
6. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA 2012; 109: 5322-5327.
7. He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci USA 2011; 108: 20054-20059.
8. Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, MLKL. J Biol Chem 2013; 288: 31268-31279.
9. Wu J, Huang Z, Ren J, Zhang Z, He P, Li Y et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res 2013; 23: 994-1006.
10. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357-1360.
11. Chen W, Zhou Z, Li L, Zhong CQ, Zheng X, Wu X et al. Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling. J Biol Chem 2013; 288: 16247-16261.
12. Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
13. Su L, Quade B, Wang H, Sun L, Wang X, Rizo J. A plug release mechanism for membrane permeation by MLKL. Structure 2014; 22: 1489-1500.
14. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16: 55-65.
15. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7: 971-981.
16. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci USA 2014; 111: 15072-15077.
17. Chen X, Li W, Ren J, Huang D, He WT, Song Y et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014; 24: 105-121.
18. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157: 1175-1188.
19. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90-94.
20. Rickard JA, erton H, Etemadi N, Nachbur U, Darding M, Peltzer N et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. eLife 2014; 3: e03464.
21. Rodriguez DA, Weinlich R, Brown S, Guy C, Fitzgerald P, Dillon CP et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ 2016; 23: 76-88.
22. Lin J, Li H, Yang M, Ren J, Huang Z, Han F et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep 2013; 3: 200-210.
23. Murakami Y, Matsumoto H, Roh M, Suzuki J, Hisatomi T, Ikeda Y et al. Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci USA 2012; 109: 14598-14603.
24. Linkermann A, Brasen JH, Darding M, Jin MK, Sanz AB, Heller JO et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 2013; 110: 12024-12029.
25. Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 2014; 20: 204-208.
26. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res 2014; 103: 206-216.
27. Zhang T, Zhang Y, Cui M, Jin L, Wang Y, Lv F et al. CaMKII is a RIP3 substrate mediating ischemia-and oxidative stress-induced myocardial necroptosis. Nat Med 2016; 22: 175-182.
28. Duprez L, Takahashi N, Van Hauwermeiren F, Vandendriessche B, Goossens V, Vanden Berghe T et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011; 35: 908-918.
29. Wong WW, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1-and RIPK3-dependent manner. Blood 2014; 123: 2562-2572.
30. Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 2015; 6: 6282.
31. Moriwaki K, Bertin J, Gough PJ, Chan FK. A RIPK3-caspase 8 complex mediates atypical pro-IL-1beta processing. J Immunol 2015; 194: 1938-1944.
32. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa B signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, Toll-like receptors 2 and 4. Mol Cell Biol 2004; 24: 1464-1469.
33. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: cardiovascular and immunological aspects. Virulence 2014; 5: 12-19.
34. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
35. Schomer DF, Marks MP, Steinberg GK, Johnstone IM, Boothroyd DB, Ross MR et al. The anatomy of the posterior communicating artery as a risk factor for ischemic cerebral infarction. N Engl J Med 1994; 330: 1565-1570.
36. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, DR3 and is lethal prenatally. Immunity 1998; 9: 267-276.
37. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-2354.
38. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol 2015; 16: 618-627.
39. Van Hauwermeiren F, Armaka M, Karagianni N, Kranidioti K, Vandenbroucke RE, Loges S et al. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest 2013; 123: 2590-2603.
40. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481-495.
41. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
42. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 2003; 278: 51613-51621.
43. Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM et al. Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol 2014; 193: 1539-1543.
44. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476-5480.
45. Kumari S, Redouane Y, Lopez-Mosqueda J, Shiraishi R, Romanowska M, Lutzmayer S et al. Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. eLife 2014; 3: e03422.
46. Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc Natl Acad Sci USA 2014; 111: 7391-7396.
47. Philip NH, Dillon CP, Snyder AG, Fitzgerald P, Wynosky-Dolfi MA, Zwack EE et al. Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-kappaB and MAPK signaling. Proc Natl Acad Sci USA 2014; 111: 7385-7390.
48. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
49. Dondelinger Y, Aguileta MA, Goossens V, Dubuisson C, Grootjans S, Dejardin E et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013; 20: 1381-1392.
50. Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013; 38: 896-905.
51. De A, Dainichi T, Rathinam CV, Ghosh S. The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling. EMBO Rep 2014; 15: 775-783.
52. Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2015; 528: 370-375.
53. Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep 2015; 13: 2258-2272.
54. Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 2007; 21: 227-233.
55. Koudstaal S, Oerlemans MI, Van der Spoel TI, Janssen AW, Hoefer IE, Doevendans PA et al. Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs. Eur J Clin Invest 2015; 45: 150-159.
56. Linkermann A, Brasen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 2012; 81: 751-761.
57. Moriwaki K, Balaji S, McQuade T, Malhotra N, Kang J, Chan FK. The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 2014; 41: 567-578.
58. Liu ZY, Wu B, Guo YS, Zhou YH, Fu ZG, Xu BQ et al. Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis inmice. Am J Cancer Res 2015; 5: 3174-3185.
59. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
60. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 2002; 277: 33275-33283.